Abstract
Aims To generate a predictive model for the SARS-COV-2 viral reproductive rate, based on government policy and weather parameters.
Methods A multivariate model for the log10 of viral reproductive rate was constructed for each country using lockdown stringency (Oxford University tracker), temperature and humidity, for the 1st 110 days of 2020. This was validated by extrapolating to the following 51 days, and comparing the predicted viral rate and cumulative mortality with WHO data.
The country models was extrapolated to July 2021 using projected weather forecast for four scenarios; continuing with the 11/6/2020 lockdown policy, 100% lockdown, 20% lockdown and no lockdown.
Results From pooled data (40 countries), lockdown stringency had a strong negative correlation with log10viral reproductive rate (−0.648 at 21 days later). Maximum temperature correlated at -0.14, 14 days later and humidity correlated at +0.25, 22 days later. Predictive Models were generated for 11 countries using multivariate regression of these parameters. The R2 correlation for log10R0 ranged from 0.817 to 0.987 for the model generation period. For the validation period, the Pearson’s coefficient of correlation ranged from 0.344 to 0.984 for log10R0 and from 0.980 to 1.000 for cumulative mortality.
Forward extrapolation of these models for 5 nations, demonstrate, that removing the lockdown will result in rapid spread of the disease ranging from as soon as July 2020 for Russia, UK, Italy and India to January 2021 for the USA. The current (11/6/20) lockdown in the USA, Spain, UK, France, Germany, Turkey can control the disease but other nations will need to intensify their lockdowns to prevent future resurgence. Most nations will require more stringent lockdowns in January than in July.
Conclusion The viral reproductive rate is highly predicted by a combination of lockdown stringency, temperature and humidity. Country specific predictive models can provide useful forecast of policy requirements.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
N/A
Funding Statement
No funding was received
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
N/A - only publically available data used
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Paper in collection COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.